Britain's antitrust regulator, the Competition and Markets Authority (CMA) on Wednesday announced that it is investigating the acquisition of LloydsDirect
by Pharmacy2U last year, and has launched its first phase of the merger inquiry.
The completed deal between two of the UK's foremost online pharmacies was announced in a joint statement issued on 9 October, confirming that they would operate
as Pharmacy2U.
Commenting on the purchase, Kevin Heath, CEO of Pharmacy2U, then said: "Combining the best of both of our businesses, we can provide patients with greater access
and convenience."
The regulator is considering "whether it is or may be the case that this merger has resulted in the creation of a relevant merger situation under the merger
provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening
of competition within any market or markets in the United Kingdom for goods or services."
The Competition and Markets Authority (CMA) has revoked its initial enforcement order imposed on Pharmacy2U Limited (Pharmacy2U) concerning the acquisition of
Metabolic Healthcare Ltd (Lloyds Direct).
In the revocation order issued on February 12, the regulator said its decision was "based on the evidence it has received in its assessment of the Merger to date."
The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Pharmacy2U, P2U Holdings Limited, G Square Capital II L.P., G Square
Healthcare Private Equity LLP (collectively, the Acquirer Group) and Lloyds Direct on 28 November 2023.
It announced that it was considering "whether it is or may be the case that a relevant merger situation has been created and whether the creation of that situation
has resulted or may be expected to result in a substantial lessening of competition in any market or markets in the United Kingdom (UK)."